RecombiMAb anti-mouse PD-L1 (B7-H1) (LALA-PG)

About RecombiMAb anti-mouse PD-L1 (B7-H1) (LALA-PG)

The 10F.9G2™-CP154 monoclonal antibody is a recombinant chimeric version of the original 10F.9G2™ antibody. The variable domain sequences are identical to the original 10F.9G2™ but the constant region sequences have been switched from rat IgG2b to mouse IgG2a. The 10F.9G2™-CP154 antibody contains a LALA-PG mutation in the Fc fragment rendering it unable to bind to endogenous Fcγ receptors. The 10F.9G2™-CP154 antibody reacts with mouse PD-L1 (programmed death ligand 1) also known as B7-H1 or CD274. PD-L1 is a 40 kDa type I transmembrane protein that belongs to the B7 family of the Ig superfamily. PD-L1 is expressed on T lymphocytes, B lymphocytes, NK cells, dendritic cells, as well as IFNγ stimulated monocytes, epithelial cells and endothelial cells. PD-L1 binds to its receptor, PD-1, found on CD4 and CD8 thymocytes as well as activated T and B lymphocytes and myeloid cells. Engagement of PD-L1 with PD-1 leads to inhibition of TCR-mediated T cell proliferation and cytokine production. PD-L1 is thought to play an important role in tumor immune evasion. Induced PD-L1 expression is common in many tumors and results in increased resistance of tumor cells to CD8 T cell mediated lysis. In mouse models of melanoma, tumor growth can be transiently arrested via treatment with antibodies which block the interaction between PD-L1 and PD-1. The 10F.9G2™ antibody has been shown to block the interaction between PD-L1 and PD-1 and between PD-L1 and B7-1 (CD80).